ライソゾーム病治療の世界市場レポート 2024年

ライソゾーム病治療市場規模は近年力強く成長しています。2023年の86億9,000万米ドルから2024年には93億3,000万米ドルへと、CAGR7.3％で拡大します。これまでの期間に見られた拡大は、治療アプローチの進歩、ライソゾーム病に対する理解と認識の向上、臨床試験と研究努力の増加、診断ツールの強化、新生児スクリーニングプログラムの開発に起因しています。

ライソゾーム病治療市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は7.8％で、125億8,000万米ドルに成長します。予測期間中に予想される成長は、遺伝子治療の進歩、酵素補充療法（ERT）の継続的開発、新しい治療法の拡大、スクリーニングと早期診断プログラムの改善、研究開発投資の増加に起因しています。予測期間における主な動向は、酵素補充療法（ERT）の革新、遺伝子治療の発展、シャペロン療法の進化、基質還元療法（SRT）の進展、新生児スクリーニングプログラムの拡大などです。

ライソゾーム病有病率の増加が予想され、ライソゾーム病治療市場の成長を牽引します。ライソゾーム病は、酵素の欠損や体内への異常物質の蓄積につながるまれな遺伝的障害を特徴とし、ライソゾーム内の蓄積物質の分解を伴う治療が必要となります。これらの疾患に対処するために、外部から合成された外因性酵素が血流に注入されます。2021年12月にLancet誌に発表された研究によると、オーストラリアにおけるライソゾーム貯蔵障害の有病率は、出生数4,800人に1人でした。この調査では、38の異なる疾患について766件の診断が確認され、小児期よりも成人期にLSDの有病率が高いことが示されました。このようなライソゾーム障害の増加は、在宅ヘルスケア機器市場の成長を促進する重要な要因です。

ライソゾーム病治療市場の成長は、ヘルスケアインフラへの投資の増加によってさらに促進されます。ヘルスケア施設やサービスの開発、維持、強化に向けた投資は、ヘルスケアの効率と患者の転帰に大きく貢献します。特に、ロシアの一次医療近代化のための連邦プロジェクトは、2023年に888億ルーブル（9億1,000万米ドル）、2023年から2025年にかけては5,500億ルーブル（57億米ドル）という多額の資金を割り当てることになっています。これは、ヘルスケア・インフラへの投資拡大がライソゾーム病治療市場にプラスの影響を与えることを裏付けています。

2023年のライソゾーム病治療市場で最大の地域は北米でした。予測期間中、世界のライソゾーム病治療市場レポートでは欧州が最も急成長する地域と予測されています。ライソゾーム病治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のライソゾーム病治療市場、疾患タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ムコ多糖症
• ポンペス症候群
• ファブリー病
• ゴーシェ病
• その他
• 世界のライソゾーム病治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 基質減少療法
• 幹細胞療法
• 酵素補充療法
• その他
• 世界のライソゾーム病治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• その他
• 世界のライソゾーム病治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック
• 在宅ケア
• その他

第7章 地域および国の分析

• 世界のライソゾーム病治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のライソゾーム病治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ライソゾーム病治療市場の競合情勢
• ライソゾーム病治療市場の企業プロファイル
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • Sanofi SA
  • Pfizer Inc.
  • Novartis International AG

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Lysosomal Disease Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lysosomal disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lysosomal disease treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The lysosomal disease treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Disease Type: Mucopolysaccharidosis; Pompes Syndrome; Fabry Diseases; Gaucher's Disease; Other Disease Types
• 2) By Therapy: Substrate Reduction Therapy; Stem Cell Therapy; Enzyme Replacement Therapy; Other Therapies
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End User: Hospitals; Specialty Clinics; Homecare; Other End Users
• Companies Mentioned: Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Sanofi SA; Pfizer Inc.; Novartis International AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Lysosomal diseases (LSDs) are characterized by the accumulation of substrates within cells of various organs due to impaired lysosomal function. This accumulation of materials in the lysosomes results in damage to various tissues and organs, giving rise to a diverse range of symptoms that can impact different parts of the body.

The primary types of treatment for lysosomal diseases encompass conditions such as mucopolysaccharidosis, Pompe's syndrome, Fabry disease, Gaucher's disease, and others. Mucopolysaccharidosis type I (MPS I), for example, is an LSD caused by a deficiency in the enzyme alpha-L-iduronidase (IDUA), and it is treated through enzyme replacement therapy (ERT) and/or hematopoietic stem cell transplantation (HSCT). Therapies for these diseases include substrate reduction therapy, stem cell therapy, enzyme replacement therapy, and other treatments administered through various routes, such as oral, parenteral, and others. These treatments are administered in settings such as hospitals, specialty clinics, home care, and other end-user environments.

The lysosomal disease treatment market research report is one of a series of new reports from The Business Research Company that provides lysosomal disease treatment market statistics, including lysosomal disease treatment industry global market size, regional shares, competitors with a lysosomal disease treatment market share, detailed lysosomal disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lysosomal disease treatment industry. This lysosomal disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lysosomal disease treatment market size has grown strongly in recent years. It will grow from $8.69 billion in 2023 to $9.33 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The expansion observed in the historical period can be attributed to advancements in therapeutic approaches, an improved understanding and awareness of lysosomal diseases, an increase in clinical trials and research efforts, enhancements in diagnostic tools, and the development of newborn screening programs.

The lysosomal disease treatment market size is expected to see strong growth in the next few years. It will grow to $12.58 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period can be attributed to advancements in gene therapy, ongoing developments in enzyme replacement therapy (ERT), the expansion of new therapeutic modalities, improved screening and early diagnosis programs, and increased investments in research and development. Major trends in the forecast period encompass innovations in enzyme replacement therapy (ERT), developments in gene therapy, the evolution of chaperone therapy, the progress of substrate reduction therapy (SRT), and the expansion of newborn screening programs.

The anticipated increase in the prevalence of lysosomal disorders is set to drive the growth of the lysosomal disease treatment market. Lysosomal diseases, characterized by rare genetic disorders leading to enzyme deficiencies and abnormal material accumulation in the body, necessitate treatment involving the degradation of stored materials within lysosomes. Exogenous enzymes synthesized externally are infused into the bloodstream to address these diseases. A study published in The Lancet in December 2021 revealed a combined prevalence of 1 per 4,800 live births for lysosomal storage disorders in Australia. The incidence involved 766 confirmed diagnoses across 38 different disorders, indicating a prevalence of LSD in adulthood more than in childhood. This rise in lysosomal disorders is a key factor propelling the growth of the home healthcare equipment market.

The growth of the lysosomal disease treatment market is further fueled by increased investments in healthcare infrastructure. Investments directed towards the development, maintenance, and enhancement of healthcare facilities and services contribute significantly to healthcare efficiency and patient outcomes. Notably, Russia's federal project for modernizing primary healthcare is set to allocate substantial funds, amounting to 88.8 billion rubles ($910 million) in 2023 and 550 billion rubles ($5.7 billion) for 2023-2025. This underscores the positive impact of growing investments in healthcare infrastructure on the lysosomal disease treatment market.

A notable trend in the lysosomal disease treatment market is the collaborative innovation for novel disease treatments. Companies within the market are forging collaborations to advance treatment solutions, employing innovative technologies to maintain their market position. An example is the collaboration between Eli Lilly, a US-based pharmaceutical company, and Lycia Therapeutics, Inc., a US-based biotechnology company, aiming to develop and commercialize targeted therapeutics using Lycia's lysosomal targeting chimera (LYTAC) protein degradation technology. Such partnerships align with the strategy of leveraging innovative technology to address challenging disease areas, including lysosomal disorders.

Major players in the lysosomal disease treatment market are strategically focusing on research and technology advancements to solidify their market presence. Research and technological progress signify continuous improvements and breakthroughs in scientific investigation and capabilities. For instance, in September 2023, Amicus Therapeutics, a US-based biopharmaceutical company, received FDA approval for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) 65mg capsules for the treatment of adult patients with late-onset Pompe disease (LOPD). This two-component therapy, comprising cipaglucosidase alfa-atga and miglustat, showcases innovative advancements in lysosomal disease treatment.

In July 2021, AstraZeneca, a UK-based pharmaceutical and biotechnology company, completed the acquiring Alexion Pharmaceuticals, Inc. (Alexion) for $39 billion. This acquisition aimed to bolster AstraZeneca's position in immunology, complementing its existing capabilities in oncology, respiratory, and cardiovascular disease. Alexion Pharmaceuticals, a US-based company, is renowned for developing treatments for rare diseases, including lysosomal disorders.

Major companies operating in the lysosomal disease treatment market report are Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Sanofi SA, Pfizer Inc., Novartis International AG, Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics Inc., Actelion Pharmaceuticals Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Merck & Co Inc., AstraZeneca PLC, Arena Pharmaceuticals Inc., Astellas Pharma Inc., Horizon Therapeutics plc, Leadient Biosciences Inc., Orphazyme A/S, Recordati Industria Chimica e Farmaceutica S.p.A., Valerion Therapeutics Llc, Viatris Inc., Chiese Farmaceutici SpA, Genzyme Corporation, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics Inc., Avrobio Inc., Axovant Gene Therapies Ltd., Regenxbio Inc., Krystal Biotech Inc., Homology Medicines Inc., Orchard Therapeutics plc, Sarepta Therapeutics Inc., Solid Biosciences Inc.

North America was the largest region in the lysosomal disease treatment market in 2023. Europe is expected to be the fastest-growing region in the global lysosomal disease treatment market report during the forecast period. The regions covered in the lysosomal disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lysosomal disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The lysosomal disease treatment market includes revenues earned by entities by offering lysosomal disease treatment services for inherited lysosomal disorders such as neuronal ceroid lipofuscinoses, Danon disease, and Wolman disease, and diagnosis of the disease through medication and therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The lysosomal disease treatment market consists of sales of medicines and services such as Bone marrow transplantation, the use of molecular chaperones, and Gene therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Lysosomal Disease Treatment Market Characteristics

3. Lysosomal Disease Treatment Market Trends And Strategies

4. Lysosomal Disease Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Lysosomal Disease Treatment Market Size and Growth

• 5.1. Global Lysosomal Disease Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Lysosomal Disease Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Lysosomal Disease Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Lysosomal Disease Treatment Market Segmentation

• 6.1. Global Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Mucopolysaccharidosis
• Pompes Syndrome
• Fabry Diseases
• Gaucher's Disease
• Other Disease Types
• 6.2. Global Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Substrate Reduction Therapy
• Stem Cell Therapy
• Enzyme Replacement Therapy
• Other Therapies
• 6.3. Global Lysosomal Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End Users

7. Lysosomal Disease Treatment Market Regional And Country Analysis

• 7.1. Global Lysosomal Disease Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Lysosomal Disease Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Lysosomal Disease Treatment Market

• 8.1. Asia-Pacific Lysosomal Disease Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Lysosomal Disease Treatment Market

• 9.1. China Lysosomal Disease Treatment Market Overview
• 9.2. China Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Lysosomal Disease Treatment Market

• 10.1. India Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Lysosomal Disease Treatment Market

• 11.1. Japan Lysosomal Disease Treatment Market Overview
• 11.2. Japan Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Lysosomal Disease Treatment Market

• 12.1. Australia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Lysosomal Disease Treatment Market

• 13.1. Indonesia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Lysosomal Disease Treatment Market

• 14.1. South Korea Lysosomal Disease Treatment Market Overview
• 14.2. South Korea Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Lysosomal Disease Treatment Market

• 15.1. Western Europe Lysosomal Disease Treatment Market Overview
• 15.2. Western Europe Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Lysosomal Disease Treatment Market

• 16.1. UK Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Lysosomal Disease Treatment Market

• 17.1. Germany Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Lysosomal Disease Treatment Market

• 18.1. France Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Lysosomal Disease Treatment Market

• 19.1. Italy Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Lysosomal Disease Treatment Market

• 20.1. Spain Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Lysosomal Disease Treatment Market

• 21.1. Eastern Europe Lysosomal Disease Treatment Market Overview
• 21.2. Eastern Europe Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Lysosomal Disease Treatment Market

• 22.1. Russia Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Lysosomal Disease Treatment Market

• 23.1. North America Lysosomal Disease Treatment Market Overview
• 23.2. North America Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Lysosomal Disease Treatment Market

• 24.1. USA Lysosomal Disease Treatment Market Overview
• 24.2. USA Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Lysosomal Disease Treatment Market

• 25.1. Canada Lysosomal Disease Treatment Market Overview
• 25.2. Canada Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Lysosomal Disease Treatment Market

• 26.1. South America Lysosomal Disease Treatment Market Overview
• 26.2. South America Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Lysosomal Disease Treatment Market

• 27.1. Brazil Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Lysosomal Disease Treatment Market

• 28.1. Middle East Lysosomal Disease Treatment Market Overview
• 28.2. Middle East Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Lysosomal Disease Treatment Market

• 29.1. Africa Lysosomal Disease Treatment Market Overview
• 29.2. Africa Lysosomal Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Lysosomal Disease Treatment Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Lysosomal Disease Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Lysosomal Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Lysosomal Disease Treatment Market Competitive Landscape
• 30.2. Lysosomal Disease Treatment Market Company Profiles
  • 30.2.1. Eli Lilly and Company
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Takeda Pharmaceutical Company Limited
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Sanofi SA
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Pfizer Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis International AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Lysosomal Disease Treatment Market Competitive Benchmarking

32. Global Lysosomal Disease Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Lysosomal Disease Treatment Market

34. Lysosomal Disease Treatment Market Future Outlook and Potential Analysis

• 34.1 Lysosomal Disease Treatment Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Lysosomal Disease Treatment Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Lysosomal Disease Treatment Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer